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Abstract
Introduction: It has recently been proposed that B lymphocytes are involved in sepsis pathogenesis. The goal of
this study is to investigate potential abnormalities in a subset distribution and activation of circulating B
lymphocytes in patients with septic shock.
Methods: This observational prospective study was conducted in a medical-surgical ICU. All patients with septic
shock were eligible for inclusion. B-cell phenotypes (CD19+CD69+, CD19+CD23+, CD19+CD5+, CD19+CD80,
CD19+CD86+, CD19+CD40 and CD19+CD95+) were assessed by quantitative flow cytometry upon admission to
the ICU and 3, 7, 14 and 28 d later.
Results: Fifty-two patients were included. Thirty-six healthy volunteers matched for age and sex were used as
controls. The patients had lymphopenia that was maintained during 28 d of follow-up. In patients with septic
shock who died, the percentage of CD19+CD23+ was lower during the 7 d of follow-up than it was in survival
patients. Moreover, the percentage of CD80+ and CD95+ expression on B cells was higher in patients who died
than in survivors. Receiver operating characteristic curve analysis showed that a CD19+CD23+ value of 64.6% at
ICU admission enabled discrimination between survivors and nonsurvivors with a sensitivity of 90.9% and a
specificity of 80.0% (P = 0.0001).
Conclusions: Patients with septic shock who survive and those who don’t have different patterns of abnormalities
in circulating B lymphocytes. At ICU admission, a low percentage of CD23+ and a high of CD80+ and CD95+ on
B cells were associated with increased mortality of patients with septic shock. Moreover, a drop in circulating
B cells persisted during 28 d of ICU follow-up.
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Introduction
Several mechanisms of the innate and adaptive immune
responses are involved in the pathogenesis of sepsis
[1,2]. The bacteria and/or bacterial components released
during infection may interact with, and induce abnormal
activation of, different cell types of the immune system.
The involvement of monocytes and phagocytic cells in
the induction of inflammatory derangement of sepsis
has been clearly established [3]. Our group and other
authors have described that T lymphocytes and natural
killer cells show several abnormalities in patients with
septic shock [4-6].
Blymphocytes are a heterogeneous cell population with
different functional and phenotypical properties [7-9].
The majority of B cells are classified as conventional B2
cells, including follicular B cells, which are characterized
by high CD23 and low CD21 expression, and marginal B
cells that express high amounts of CD21 [10,11]. The
minority B-1 B-lymphocyte population is classified into
B-1a and B-1b subsets based on cell-surface CD5 expres-
sion. B-1a cells have an exclusive fetal origin and are
characterized by CD5 expression (CD5+) and CD23-/low,
produce natural antibodies, IL-10 and inhibition of T
cells. B-1b cells can be of adult origin, do not express
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CD5 (and CD23-/low) and respond to particulate antigens
and polysaccharide [12].
B cells play a pivotal role in both adaptive and innate
immune response [13]. During the immune response
against infectious agents, B lymphocytes play a relevant
role by different mechanisms, including the production
of antibodies and the presentation of microorganism
antigens to T lymphocytes [14]. Furthermore, the inter-
action of several bacterial products with B cells may
cause their activation and cytokine secretory function
[15-17].
The role of B lymphocytes in the pathogenesis of sepsis
has not been established. It has been reported that
patients who have recovered from an episode of invasive
pneumococcal disease show defective B-cell activation
[18]. It has been demonstrated that innate response acti-
vator B (IRA-B) cells play a critical role in the response to
sepsis [19,20]. It has been proposed that B cells might
contribute to the immunosuppressive shift observed dur-
ing sepsis [21].
In this study, we investigated the presence of abnormal-
ities in the B-cell compartments of patients with septic
shock and analyzed its relevance to the evolution of sepsis
and the prognosis of these patients. In this study, we inves-
tigated the number and distribution of B cells, as well as
their expression of activation/redistribution (CD69, CD23
and CD5), costimulation (CD80, CD86 and CD40) and
programmed cell death regulation (CD95) antigens in 52
patients with septic shock at admission to the ICU at our
institution and at days 3, 7, 14 and 28 of follow-up. Sex-
and age-matched healthy donors were studied in parallel
as experimental normal controls.
Materials and methods
Patient eligibility
The study was performed at the Principe de Asturias
University Hospital over a period of 36 months. The
study was conducted according to the guidelines of the
1975 Declaration of Helsinki. Approval was obtained
from the Hospital Universitario Príncipe de Astúrias
Institutional Ethics Committee. Written informed con-
sent was obtained from each participant included in the
study or from his or her relatives. The individuals
enrolled were patients diagnosed with septic shock who
had clinical evidence of infection, defined as the presence
of a known source of infection, and who had been started
on parenteral antimicrobial therapy. Septic shock was
defined as sepsis-induced hypotension despite adequate
fluid resuscitation along with the presence of perfusion
abnormalities that could include, but were not limited to,
lactic acidosis, oliguria or an acute alteration in mental
status. Patients receiving inotropic or vasopressor agents
for arterial hypotension were considered to be in septic
shock [22]. All the patients received conventional
intensive care, and included patients were treated by phy-
sicians who were not involved in this study. Patients trea-
ted with hydrocortisone for refractory hypotension were
withdrawn from the study. No patient was treated with
activated protein C.
The exclusion criteria were (1) subjects with immuno-
deficiency or who were being treated with any form of
immunomodulation therapy, including low-dose corti-
costeroids for septic shock; (2) autoimmune or hyper-
sensitivity diseases; (3) disseminated malignancy; and (4)
participation in another research study.
Thirty-six age- and sex-matched healthy blood donors
were studied in parallel with the patients. They were stu-
died to control for the adequacy of the cytometric techni-
ques and cellular culture procedures, as well as for
characterization of the normal range of the B-lymphocyte
compartment parameters analyzed.
Blood samples
Upon patients’ admission to the ICU and after their
informed consent had been obtained, blood samples were
collected into sterilized, silicone-coated glass tubes.
Blood samples were also obtained from each included
patient at days 3, 7, 14 and 28 of follow-up. In patients
who did not survive, the samples included in the analysis
were those obtained prior to the fatal outcome. Blood
samples were prepared within 1 h of sample collection
for flow cytometry.
Cell separation
Peripheral blood mononuclear cells (PBMCs) were
purified from blood by Ficoll-Hypaque (Lymphoprep
Axis-Shield; PoC AS, Oslo, Norway) density gradient
centrifugation [23]. Cells were resuspended (106 cells/ml)
in RPMI 1640 medium (BioWhittaker, Basel, Switzerland)
supplemented with 10% heat-inactivated fetal bovine
serum (Gibco/Invitrogen, Carlsbad, CA, USA), 25 mM 2-
[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
(HEPES) and 1% penicillin-streptomycin (both from
BioWhittaker).
Flow cytometry analysis
B cells were phenotypically analyzed in PBMCs by four-
color flow cytometry in a FACSCalibur flow cytometer
using CellQuest 3.3 software (BD Biosciences, San Jose,
CA, USA). PBMCs were incubated with combinations of
fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-
and phycoerythrin-cyanine 5 (TC, Tricolor)-labeled mono-
clonal antibodies (mAb). The mAb were CD3-PerCP,
CD3-FITC, CD56-PE, CD95-FITC, CD69-FITC, CD80-
PE, CD23-PE (BD Biosciences), CD5-FITC, CD19-TC
(Caltag Laboratories, San Francisco, CA, USA) and CD86-
FITC, CD40-PE (AbD Serotec, Kidlington, UK). For an
adequate experimental staining control, the appropriate
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irrelevant anti-mouse isotype controls IgG1-FITC, PE, TC
or IgG2a FITC, PE and TC (Caltag Laboratories) were
used.
Assessment of absolute number of lymphocytes
The absolute numbers of B-lymphocyte subsets were cal-
culated according to standard flow cytometry criteria for
lymphocyte subset identification. First, we calculated the
percentage of cells expressing CD19 in the total lympho-
cytes gate defined by forward and side scatter in PBMCs.
The absolute number of circulatory B lymphocytes was
calculated by determining the percentage of CD19+ cells
in peripheral blood lymphocytes multiplied by the total
number of lymphocytes per microliter measured using a
Coulter LH instrument (Beckman Coulter, Fullerton,
CA, USA). Next, we obtained the absolute number of
CD19+ (CD23+, CD69+, CD5+, CD80+, CD86+, CD40+
or CD95+) by multiplying the total number of B lympho-
cytes previously calculated by the percentage of positive
cells for each one of these antigens in CD19+ B cells. All
absolute numbers are expressed as cells per milliliter.
Statistical analyses
All statistical tests were performed using SPSS for Win-
dows version 15.0 software (SPSS, Chicago, IL, USA). Data
are expressed as means ± SEM. Because most variables
did not always fulfill the normality hypothesis, differences
between groups were analyzed using the Mann-Whitney
U-test for nonparametric data and analysis of variance fol-
lowed by a Wilcoxon signed-rank test were used for
within-group analyses. The reliability of the use of differ-
ent phenotype markers concentrations or of main clinical
variables to predict death due to septic shock was calcu-
lated by plotting receiver operating characteristic (ROC)
curves. The level of significance was set at P < 0.05.
Results
Characteristics of patients with septic shock
During the 36-month study period, a total of 92 patients
with septic shock treated at our institution were identi-
fied (Figure 1). All patients were treated with vasopres-
sors. Patients treated with hydrocortisone for refractory
hypotension were withdrawn from the study. Forty of
these patients were excluded for the following reasons:
3 patients had AIDS, 18 patients were on glucocorticoid
therapy, 12 patients were on chemotherapy, 5 patients
had metastatic cancer, 1 patient had rheumatoid arthritis
and 1 patient was excluded due to anaphylactic shock.
The mean age of the healthy controls was 62.0 ± 3.4 yr vs
61.2 ± 3.2 yr in patients with septic shock (P > 0.05), and
the gender distribution was similar: 24 males (66.6%) and
13 females in the healthy control group vs 36 males
(69.2%) and 16 females in the group of patients with sep-
tic shock (P > 0.05).
Table 1 provides demographic data for the 52 patients
ultimately included in the study. Twenty-two patients
(42.3%) had intraabdominal infections, 16 (30.7%) had
pneumonia, 4 (7.4%) had bacteremia of unknown origin,
4 (7.4%) had pyelonephritis, 3 (5.7%) had soft-tissue and
skin infections, 2 (3.8%) had surgical site infections and 1
(1.9%) had mediastinitis. The diagnosis of infection was
made on clinical grounds in 24 patients (46.1%), and posi-
tive cultures were obtained from normally sterile sites in 28
patients (53.9%). Gram-positive cocci were isolated in 11
(21.1%) of these patients, Gram-negative organisms were
isolated in 10 patients (19.2%) and polymicrobial flora were
isolated in the remaining 7 patients (13.4%). The percentage
of the 52 septic shock patients who had positive blood cul-
ture was 30.2%. No patient had fungal sepsis or septic
shock due to viruses. Bivariate analysis failed to demon-
strate a correlation between the sources of infection, the
pathogens isolated and mortality. There were no differences
in the lymphocyte profiles of patients who had Gram-posi-
tive bacterial sepsis versus Gram-negative bacterial sepsis.
Severe lymphopenia, including B-lymphocyte population,
in septic shock
Upon ICU admission, total blood lymphocyte cell count
was significantly diminished in patients with septic shock
compared with healthy controls (1,144 ± 67 cells/μl vs
2,095 ± 67 cells/μl, respectively; P < 0.05). This lympho-
penia was maintained independently of survival outcome
during 28 d of follow-up in patients with septic shock.
The absolute number of CD19+ B cells was also signifi-
cantly lower in patients with septic shock than in normal
donors upon ICU admission (208 ± 45 cells/μl vs 238 ±
13 cells/μl, respectively; P < 0.05). The numbers of these
circulating lymphocyte populations remained signifi-
cantly decreased during the 28 days of follow-up (183 ±
45 cells/μl at day 3 and 116 ± 38 cells/μl at day 7, 175 ±
54 cells/μl at day 14 and 120 ± 32 cells/μl at day 28; P <
0.05). At the times analyzed (at ICU admission and at
days 3 and 7 of follow-up), because no additional patient
died between days 7 and 28, there were no differences
between survivors and nonsurvivors regarding the num-
bers of the circulating CD19+ B lymphocytes.
Redistribution of B-lymphocyte subsets in septic shock
patients
Next, we investigated the subset distribution and activa-
tion of circulating CD19+ B lymphocytes by means of ana-
lysis of their expression of CD23+, CD69+ and CD5+
antigens in patients with septic shock and in healthy con-
trols. CD23 is expressed mainly by activated regulatory B
cells. CD69 is also expressed by early activated B cells.
CD5+CD19+ represents the B1a subset of B cells.
We observed that the circulating numbers of the
CD19+CD23+ B-lymphocyte subsets were significantly
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reduced in septic shock patients at ICU admission, inde-
pendently of their survival outcome. However, the per-
centage of the CD19+CD23+ B lymphocyte subset was
significantly increased in septic shock survivors com-
pared to nonsurvivors at ICU admission and during the
7 days of follow-up. Interestingly, we observed that the
significantly increased percentage of the CD19+CD23+
B-lymphocyte subset found in survivors at ICU admis-
sion normalized after 28 days of follow-up (Figure 2A).
A prediction ROC curve was then used to estimate the
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Figure 1 Screening and enrollment.
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value of the percentage of CD19+CD23+ B cells to pre-
dict death in patients with septic shock at admission. As
shown in Figure 3, for the percentage of CD19+CD23+
B cells, a cut-off value of 64% showed sensitivity of
90.9% (95% confidence interval (CI) = 75.6% to 98.0%)
and specificity of 80.0% (95% CI = 61.4% to 92.0%) for
predicting the risk of death, with a positive predictive
value of 89.4% and a negative predictive value of 82.7%.
The area under the ROC curve was 0.818 ± 0.055 (95%
CI = 0.701 to 0.904; P = 0.0001). Next, we selected
APACHE II score for the comparative analysis of the
outcome because it was the best prognostic clinical
score in our series. When we analyzed the ROC curve
of the Acute Physiology and Chronic Health Evaluation
II (APACHE II) score for predicting death in patients
with septic shock at admission, we found the area under
the ROC curve to be 0.721 ± 0.83 (95% CI = 0.559 to
Table 1 Demographic data of the study patients with
septic shock.
Parameters Survivors Nonsurvivors P
Number of patients (%) 34 (65.4%) 18 (34.6%)
Mean age (yr) 61.0 ± 3.2 64.5 ± 4.1 0.57
Men/women (n) 21/13 15/3 0.11
Medical/surgical patients 13/21 11/7 0.12
Mean APACHE II score 21.6 ± 1.3 29.2 ± 1.5 0.001
Mean MODS score 6.6 ± 0.5 9.5 ± 0.9 0.014
Mean Δ-MODS 2.2 ± 0.3 3.5 ± 0.7 0.169
Mean SOFA score 7.9 ± 0.6 10.6 ± 0.8 0.021
Mean Δ-SOFA 1.7 ± 0.4 2.9 ± 0.9 0.34
Categorical variables are expressed as number of patients, and continuous
variables are expressed as means ± SEM. APACHE II, Acute Physiology and
Chronic Health Evaluation II [39]; SOFA, Sepsis-Related Organ Failure
Assessment [40]; MODS, Multiple Organ Dysfunction Score [41]; Δ-MODS is the
difference between the maximum and initial MODS scores [42], and Δ-SOFA is
the difference between the maximum and initial SOFA scores [43].
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Figure 2 Time course of the percentages of CD19+ lymphocytes that express CD23+ (A), CD69+ (B), CD5+ (C), CD95+ (D) and CD80+
(E) antigens in patients with septic shock during their stay in the ICU. Data presented are for survivors (black triangles) and nonsurvivors
(white triangles). The dotted line represents the mean value recorded in the healthy controls (n = 36). At ICU admission, study patients were 34
survivors and 18 nonsurvivors; at day 3, 34 survivors and 13 nonsurvivors; at day 7, 34 survivors and 11 nonsurvivors; at day 14 and at day 28, 34
survival patients were studied. All values are expressed as means ± SEM. *P < 0.05 for survivors or nonsurvivors vs healthy controls; †P < 0.05 for
survivors vs nonsurvivors.
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0.883) and a cut-off value of 23 showed sensitivity of
76.9% and specificity of 60.7% (P = 0.024).
In contrast to the observed diminution of the absolute
number of total circulating CD19+ B lymphocytes and
CD19+CD23+ B cells, we found that the CD19+CD69+
B-cell subset count was normal in both survival and
nonsurvival septic shock patients at ICU admission.
Furthermore, the percentage of CD19+CD69+ PBMCs
was elevated in both groups of septic shock patients at
ICU admission and during the 28 days of follow-up
(Figure 2B).
The number of circulating CD5+CD19+ B lymphocytes
was significantly reduced in patients with septic shock (at
ICU admission, 46 ± 11 cells/μl; at day 3, 46 ± 21 cells/μl;
at day 7, 31 ± 14 cells/μl; at day 14, 50 ± 10 cells/μl; and
at day 28, 41 ± 5 cells/μl in septic shock patients and
63 ± 5 cells/μl in healthy controls). There were no differ-
ences in the percentage of circulating CD5+CD19+ cells
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Figure 3 Receiver operating characteristic (ROC) curve analysis of percentages of CD19+CD23+, CD19+CD80+ and CD19+CD95+ for
predicting the risk of death at ICU admission. For CD19+CD23+, a cut-off value of 64% showed sensitivity of 90.9% (95% confidence interval
(CI) = 75.6% to 98.0%) and specificity of 80.0% (95% CI = 61.4% to 92.0%) for predicting the risk of death, with a positive predictive value of
89.4%, a negative predictive value of 82.7% and area under the ROC curve 0.818 ± 0.055 (95% CI = 0.701 to 0.904; P = 0.0001). For CD19+CD80+
and CD19+CD95+, respectively, cut-off values of 20% and 17% showed sensitivity of 81.8% (95% CI = 64.5% to 92.8%) and 81.9% (95% CI =
64.2% to 93.0%) and specificity of 70% (95% CI = 50.6% to 85.2%) and 75% (95% CI = 53.3% to 90.2%) for predicting the risk of death on day 28,
with the area under the ROC curve 0.751 ± 0.061 (95% CI = 0.630 to 0.854) and 0.795 ± 0.058 (95% CI = 0.668 to 0.891) (P = 0.0001 for both).
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Figure 4 Two representative CD19+CD23+ flow cytometry samples at basal time.
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between both groups of septic patients and healthy
donors at baseline and during the follow-up (Figure 2C).
We also investigated the expression of apoptotic sus-
ceptibility CD95 antigen on the surface of B lympho-
cytes from patients and healthy donors. The absolute
number of circulating CD19+CD95+ B cells found in
septic shock patients at ICU admission was similar to
that of healthy donors (Table 2). However, the percen-
tage of CD19+CD95+ B cells was significantly higher in
nonsurvivors than in survivors at ICU admission and
normalized after 7 days of follow-up (Figure 2D).
We also studied the expression of the CD80, CD86 and
CD40 on B lymphocytes from patients and healthy donors.
CD80, CD86 and CD40 are membrane molecules that play
a critical role in the stimulation of T lymphocytes by B
lymphocytes acting as antigen-presenting cells. As shown
in Table 2, the absolute number of circulating CD19+ B
cells expressing CD80+ or CD86+ was normal in septic
shock patients at ICU admission. When we analyzed the
behavior of survivors and nonsurvivors, we found that the
percentage of CD19+CD80+ B cells was significantly
increased in nonsurvival septic patients with respect to
survivors at ICU admission and healthy controls (P <
0.05). A normalization of this percentage was observed
after 3 d of follow-up (Figure 2E).
A significant reduction of circulating CD19+CD40+ B
cells was found in septic shock patients at ICU admission
compared to healthy donors (Table 2). There were no
significant differences between the percentages of CD19+
CD40+ B cells found in survivors and nonsurvivors.
There were no significant differences in the number of
circulating CD19+ B lymphocytes and in its cell subset
distribution during the 28 d of the study (Figure 2 and
data not shown).
Discussion
In this paper, we report that septic shock patients have a
severe retraction of circulating B lymphocytes. This lym-
phopenia affects the B-cell subsets heterogeneously, with
marked reduction of CD19+CD23+ and CD19+CD5+ B
cells but normal numbers of CD19+CD69+ B cells.
Furthermore, a different distribution of B cells subsets is
found in survivor and nonsurvivor septic shock patients.
The percentage of CD19+CD23+ B lymphocytes appears
to be a biomarker for the prognosis of outcome of septic
shock patients. These data support a role for the B-cell
compartment in septic shock patients and are in agree-
ment with those published in previous studies [24-26].
It is established that septic shock is associated with a
severe exhaustion and depletion of T lymphocytes [27].
Our data support similar behavior in the B-lymphocyte
compartment. We have found that the reduction of circu-
lating B cells affects the different B-cell subsets heteroge-
neously in septic shock patients and that those different
patterns of involvement are observed in survivor and non-
survivors. CD23 is a low-affinity receptor for IgE located
at the surface of B cells [28]. CD23 is involved in different
regulatory functions, such as enhancing antigen presenta-
tion, improving cell differentiation and growth and regu-
lating IgE synthesis [28]. Some authors have reported that
CD23 is expressed on activated B cells, whereas others
have suggested that peripheral blood CD23 B cells resem-
ble classic memory cells [28]. Our data presented herein
show that circulating CD19+CD23+ B lymphocytes are
Table 2 Peripheral blood cell count of B-lymphocyte subsets and their percentage in the compartment of circulating
B lymphocytes in patients with septic shock and in healthy controls at ICU admissiona
Lymphocyte blood cell count (cells/μl) Subset Healthy controls Septic shock patients
CD19+ 238.5 ± 13.2 208.1 ± 45.4*
CD19+CD23+ 148.3 ± 11.2 102.5 ± 17.8*
CD19+CD69+ 5.4 ± 1.0 7.1 ± 2.5
CD19+CD5+ 63.5 ± 5.2 44.5 ± 7.8*
CD19+CD80+ 73.6 ± 6.5 60.5 ± 15.8
CD19+CD86+ 35.9 ± 3.4 47.6 ± 10.2
CD19+CD40+ 223.5 ± 15.5 130.7 ± 21.6*
CD19+CD95+ 37.8 ± 2.7 30.3 ± 4.7
Percentage of CD19+ (%) Subset Healthy controls Septic shock patients
CD19+CD23+ 57.4 ± 1.7 62.7 ± 4.6
CD19+CD69+ 2.6 ± 0.5 9.0 ± 2.1*
CD19+CD5+ 25.3 ± 1.5 24.6 ± 3.1
CD19+CD80+ 29.6 ± 1.7 32.4 ± 4.4
CD19+CD86+ 16.1 ± 1.2 36.7 ± 7.2*
CD19+CD40+ 94.6 ± 1.2 95.7 ± 1.5
CD19+CD95+ 16.1 ± 1.1 25.7 ± 4.7*
aData are expressed as mean ± SE mean. *P < 0.05 between patients with septic shock and healthy controls.
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clearly decreased in septic shock patients because their
percentage in the whole circulating B cell compartment is
different in survivors and nonsurvivors. We have found
that higher percentages of circulating CD19+CD23+ are
associated with better clinical outcomes of patients with
septic shock. Interestingly, the number of CD19+CD69+
early activated B cells in septic shock patients is similar to
that found in healthy donors and is not related to the clin-
ical prognosis of the patient.
Taking the behavior of both CD19+CD23+ and CD19+
CD69+ B lymphocytes together, it can be speculated that
the depletion of B cells in septic shock patients is an event
that preferentially occurs after the initiation of their
in vivo activation. The intensity of this event might corre-
late with the observed reduction of activated B cells and is
associated with the clinical outcome of the patient. More-
over, we have compared this finding with the APACHE II
scores, because APACHE II score was the best prognostic
clinical variable that we analyzed. When we analyzed the
ROC curve of APACHE II score for predicting death in
patients with septic shock at admission, we found that B-
lymphocyte data are significantly more accurate than the
APACHE II score for predicting death.
In addition to the observed changes in the distribution
of the cell subsets of the circulating B-lymphocyte com-
partment, we investigated the expression of the function-
ally critical antigens CD80 and CD86 on these B cells. In
murine studies of sepsis, an important role for CD80 and
CD86 antigens in the response to sepsis has been estab-
lished [29,30]. Our data presented herein show a higher
percentage of CD86 expression in circulating CD19+ B
cells in patients with septic shock than in healthy controls.
Furthermore, at ICU admission, nonsurvivors showed
more elevated percentages of CD19+CD80+ B cells than
found in survivors. These findings in B lymphocytes of
patients with septic shock are consistent with the
increased expression of CD86 and decreased expression of
CD80 in dendritic cells found in human sepsis [31].
Apoptosis is the process of programmed cell death that
occurs to limit damage of surrounding tissue. It is critical
for the survival of many cells, including lymphocytes.
Deregulated apoptotic immune cell death has been pro-
posed to play a major role in immune dysfunction and
mortality during sepsis [32,33]. Immunohistological stu-
dies of different tissues have demonstrated increased
apoptosis of cells of the innate and adaptive immune sys-
tem in sepsis [25,34,35]. In this work, we show that the
total number of circulating B lymphocytes was low in
patients with septic shock at ICU admission and during
the following 28 days. We also observe that circulating B
cells of septic shock patients showed increased expression
of CD95 antigen. Similar findings have been described in
circulating T cells [36]. In support of the concept that
lymphocyte apoptosis is detrimental to host survival, a
number of studies have shown an inverse correlation
between lymphocyte count and survival [34,36]. In agree-
ment with this, we found a higher percentage of CD95
expression on B cells from nonsurvivors than from survi-
vor patients or healthy controls. This finding suggests that
the increased expression of CD95 on B cells from septic
shock patients might be involved in the mechanism of the
observed reduction of circulating B cells in these patients.
Several limitations of our study should be noted. The per-
ipheral blood may not represent the situation in all lym-
phoid compartments of the body, and these findings do
suggest that not all cell populations may play equal roles in
driving inflammatory and anti-inflammatory responses in
septic shock [21]. All blood samples were collected upon
ICU admission within 12 hours after inclusion criteria were
met, but the length of time that the patients were in shock
in the emergency room before admission or in the operat-
ing room is a source of inaccuracy. Recently, early altera-
tions of the innate and adaptive immune status according
to the type of underlying infection in sepsis have been
reported [37]. In addition, other factors, such as host genetic
polymorphisms or the characteristics of the pathogen, may
also have introduced variability. The average of age of our
population was 61 years. It is known that the overall num-
ber of B cells seems to moderately decline with age, but B-
lymphocyte subset studies are frequently controversial [38].
This is the reason why our control group was age-matched.
CD23 is the low-affinity immunoglobulin E (IgE) receptor
and binds both IgE and CD21 and, through these interac-
tions, regulates the synthesis of IgE, the antibody isotype
that mediates the allergic response. The expression of CD23
on B cells is higher in persons with asthma or atopy and in
patients with disorders characterized by chronic inflamma-
tion [28]. We excluded patients who were undergoing glu-
cocorticoid therapy or were in anaphylactic shock, but
patients with a personal history of chronic asthma without
hypersensitivity disease were included.
Conclusions
Septic shock is associated with a severe abnormality of cir-
culating B lymphocytes. At ICU admission, the expression
of CD23+, CD95+ or CD80+ on B cells was significantly
associated with increased 28-day mortality. These results
highlight the potential importance of B lymphocytes in
septic shock.
Key messages
• Sepsis-induced immune dysfunction may contribute to
mortality to a great degree. It is increasingly clear that
B-cell function beyond the production of immunoglobu-
lins. However, little is known about how B cells affect
innate immunity during bacterial sepsis.
• We found that patients with septic shock had B-cell
lymphopenia that was maintained during 28 days of
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follow-up. The increased expression of CD95 on B cells
suggests that apoptosis susceptibility is involved in the
reduction of circulating B cells in these patients.
• B-cell lymphopenia affects the B-cell subsets hetero-
geneously, with marked reduction of CD19+CD23+ B
cells (activated regulatory B cells) and CD19+CD5+ B
cells (natural responder B-1a cells), but with normal
numbers of CD19+CD69+ early activated B cells.
• At ICU admission, a higher percentage (64%) of CD19
+CD23+, a marker of activation and regulation, appears to
be a reliable biomarker of good outcome for patients with
septic shock, whereas the percentages of CD80+ (a T-cell
costimulation marker) and CD95+ (a marker of apoptosis
susceptibility) on B cells were significantly lower in survi-
vors than in nonsurvivors.
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